NOVEMBER 2015 ARTICLE LIST >>
PharmaTutor (November- 2015)
Print-ISSN: 2394 - 6679
e-ISSN: 2347 - 7881
(Volume 3, Issue 11)
Received On: 09/07/2015; Accepted On: 16/07/2015; Published On: 01/11/2015
AUTHOR:
Vivek P. Chavda
Department of Pharmaceutics,
B.K. Mody Government Pharmacy College,
Gujarat technological university, Rajkot, Gujarat, India
vivek7chavda@gmail.com
ABSTRACT: The goal of tailor-made medicine is to maximize the likelihood of therapeutic efficacy and to minimize the risk of drug toxicity for an individual patient. It involves right drug & dose, right patient and at right time administration of a medication. By averting the knowledge of gene sequence and their functions, biomedical research are diversified towards inter-individual variations that are expected to become an eminent part of treatment planning in terms of efficacy and toxic side effects of drugs. Tailor-made medicine focuses on individualized drug treatment according to each patient’s molecular diagnosis and genetic makeup. Genomic-based diagnostics can play a key role in creating a more efficient healthcare system by directing patients toward beneficial therapies and away from therapies that pose substantial risk or are unlikely to improve outcomes for the patient.
How to cite this article: Chavda VP; Tailor-made Medicine: A step towards future of Diagnostics and Therapeutics; PharmaTutor; 2015; 3(11); 25-28
[ABSTRACT WITH CITATION] [VIEW AS HTML]
REFERENCES:
1. Rua˜no, G., et al., Pharmacogenomic data submissions to the FDA: Clinical pharmacology case studies. Pharmacogenomics 2004; 5(5); 513–517.
2. Verma M, et al; Proteomic approaches within the NCI early detection research network for the discovery and identification of cancer biomarkers. Ann. NY Acad. Sci., 2001. 945; 103–115.
3. Pharmacogenomics fact sheet, N.C.f.B.I.N.h.w.n.n.n.g.A.p.p.h.
4. Fleck L.M; Pharmacogenomics and personalized medicine: wicked problems, ragged edges and ethical precipices; New Biotechnology; 2012; 29(6); 757-769.
5. Mehrotra N and Soni R; Pharmacogenomics: A Step Towards Personalized Medicine. Bioinformatic india, 2005; 3(4); 11-17.
6. Chavda VP and Gohil K; Proteomic and advanced technique in diagnosis and therapeutics, in Pharmacology; VNSGU: Maliba pharmacy college. 2010; 80.
7. Report F; Commonwealth of Australia. A Healthier Future for all Australians. National Health and Hospitals Reform Commission. 2009; 65.
8. Todd J.A; Metagenomics and Personalized Medicine; cell; 2011; 147; 44-57.
9. Ludwig J A and Weinstein J N; Biomarkers in cancer staging, prognosis and treatment selection. Nat. Rev. Cancer 2005; 5(11); 845–856.
10. Vaidyanathan G; Redefining Clinical Trials: The Age of Personalized Medicine; cell; 2012; 148; 1079.
11. Elizabeth Gray, Jack D. Hidary, and D. Pickar; Pharmacogenomics-based system for clinical applications, in WO 2003039234 A22004.
12. Gasche Y, Daali Y, and Fathi M; Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N. Engl. J. Med., 2004; 351(27); 2827-2831.
13. Ginsburg GS; Personalized medicine: revolutionizing drug discovery and patient care; TRENDS in Biotechnology; 2001. 19(12); 491-96.
14. NHMRC, Clinical Utility of Personalised Medicine. Information for health professionals, 2011; 1-9.
15. Pirmohamed M; Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients; British Medical Journal 2004; 329; 15-19.
16. Bansal V, Kumar V, and Medhi B; Future Challenges of Pharmacogenomics in Clinical Practice; JK Science, 2005; 7(3); 176-179.
17. Christian Ehnholm, et al.; Identification of SNPs associated with hyperlipidemia, dyslipidemia and defective carbohydrate metabolism, in WO 2005077974 A12005.
.png)
